Progress pre-clinical development of compounds for leishmaniasis
current phase of drug development
updated 29 Feb 2020
In April 2017, DNDi and GSK entered into an agreement for the pre-clinical development of two compounds for leishmaniasis which were discovered by GSK in collaboration with the Drug Discovery Unit (DDU) at the University of Dundee, following some co-funding by the Wellcome Trust.
News & press releases
Get our latest news, personal stories, research articles, and job opportunities.